Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA lays out 2010 advisory committee slate

This article was originally published in The Tan Sheet

Executive Summary

The agency's tentative 1schedule for advisory committee meetings includes a Food meeting May 20-21 and Pediatric sessions in March, June, September and December. FDA's calendar, published Dec. 30 in the Federal Register, also pencils in meetings for both the Risk Communication panel and Science Board in February, May, August and November. The Nonprescription Drug Advisory Committee has not had tentative or firm meeting dates set. NDAC last met in June 2009 for a joint session regarding acetaminophen with the Drug Safety and Risk Management and Anesthetic and Life Support Drugs committees (2"The Tan Sheet" July 6, 2009)

You may also be interested in...

NDAC meeting on calendar

FDA tentatively schedules a joint meeting of the Nonprescription Drug Advisory Committee and the Drug Safety and Risk Management Advisory Committee Sept. 14, the agency's Web site says. If the meeting is scheduled, the subject will not be known until FDA posts a Federal Register notice or updates meeting materials on its site. NDAC last met in June 2009, also with DSRM and the Life Support Drugs committee, to discuss acetaminophen (1"The Tan Sheet" Jan. 4, 2010, In Brief)

Acetaminophen OTC Combos Are Not Out Of The Woods, Despite Panel Vote

While FDA may not decide to discontinue all OTC products combining acetaminophen with other ingredients, manufacturers of combinations cannot assume all such products will avoid further scrutiny

Orphazyme Raises Funds, Approaching Markets With Novel Niemann-Pick Therapy

Denmark’s Orphazyme has raised more funds to market its lead product, the heat shock protein amplifier, arimoclomol, in the US and Europe, and to evaluate the compound for other lysosomal storage and neurodegenerative disorders.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts